In vitro sensitivity of xenograft cells to vincristine and dexamethasone
. | Vincristine . | . | Dexamethasone . | . | ||
|---|---|---|---|---|---|---|
| Xenograft . | IC50 (nM) . | Cell survival at 10 nM (% of control ± SE) . | IC50 (nM) . | Cell survival at 10 nM (% of control ± SE) . | ||
| ALL-2 | < 1 | 28.7 ± 2.7 | > 1000 | 90.8 ± 1.3 | ||
| ALL-3 | 2.5 | 18.2 ± 1.1 | 9.4 | 49.4 ± 6.7 | ||
| ALL-4 | 6.3 | 42.4 ± 10.9 | 109 | 82.6 ± 1.1 | ||
| ALL-7 | 2.9 | 41.3 ± 6.7 | > 1000 | 78.7 ± 2.5 | ||
| ALL-8 | < 1 | 35.0 ± 0.8 | 105 | 94.4 ± 14.2 | ||
| ALL-10 | 1.7 | 9.8 ± 0.8 | > 1000 | 94.3 ± 2.6 | ||
| ALL-11 | 2.8 | 25.5 ± 6.4 | 3.5 | 33.5 ± 12.9 | ||
| ALL-16 | < 1 | 23.5 ± 7.1 | 4.1 | 27.0 ± 1.8 | ||
| ALL-17 | 6.9 | 48.3 ± 5.2 | 8.9 | 48.8 ± 4.8 | ||
| ALL-19 | 10.8 | 51.5 ± 6.1 | > 1000 | 106 ± 7.3 | ||
. | Vincristine . | . | Dexamethasone . | . | ||
|---|---|---|---|---|---|---|
| Xenograft . | IC50 (nM) . | Cell survival at 10 nM (% of control ± SE) . | IC50 (nM) . | Cell survival at 10 nM (% of control ± SE) . | ||
| ALL-2 | < 1 | 28.7 ± 2.7 | > 1000 | 90.8 ± 1.3 | ||
| ALL-3 | 2.5 | 18.2 ± 1.1 | 9.4 | 49.4 ± 6.7 | ||
| ALL-4 | 6.3 | 42.4 ± 10.9 | 109 | 82.6 ± 1.1 | ||
| ALL-7 | 2.9 | 41.3 ± 6.7 | > 1000 | 78.7 ± 2.5 | ||
| ALL-8 | < 1 | 35.0 ± 0.8 | 105 | 94.4 ± 14.2 | ||
| ALL-10 | 1.7 | 9.8 ± 0.8 | > 1000 | 94.3 ± 2.6 | ||
| ALL-11 | 2.8 | 25.5 ± 6.4 | 3.5 | 33.5 ± 12.9 | ||
| ALL-16 | < 1 | 23.5 ± 7.1 | 4.1 | 27.0 ± 1.8 | ||
| ALL-17 | 6.9 | 48.3 ± 5.2 | 8.9 | 48.8 ± 4.8 | ||
| ALL-19 | 10.8 | 51.5 ± 6.1 | > 1000 | 106 ± 7.3 | ||